486 related articles for article (PubMed ID: 25295500)
1. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Pai SY; Gaspar HB; Armant M; Berry CC; Blanche S; Bleesing J; Blondeau J; de Boer H; Buckland KF; Caccavelli L; Cros G; De Oliveira S; Fernández KS; Guo D; Harris CE; Hopkins G; Lehmann LE; Lim A; London WB; van der Loo JC; Malani N; Male F; Malik P; Marinovic MA; McNicol AM; Moshous D; Neven B; Oleastro M; Picard C; Ritz J; Rivat C; Schambach A; Shaw KL; Sherman EA; Silberstein LE; Six E; Touzot F; Tsytsykova A; Xu-Bayford J; Baum C; Bushman FD; Fischer A; Kohn DB; Filipovich AH; Notarangelo LD; Cavazzana M; Williams DA; Thrasher AJ
N Engl J Med; 2014 Oct; 371(15):1407-17. PubMed ID: 25295500
[TBL] [Abstract][Full Text] [Related]
2. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1.
Mamcarz E; Zhou S; Lockey T; Abdelsamed H; Cross SJ; Kang G; Ma Z; Condori J; Dowdy J; Triplett B; Li C; Maron G; Aldave Becerra JC; Church JA; Dokmeci E; Love JT; da Matta Ain AC; van der Watt H; Tang X; Janssen W; Ryu BY; De Ravin SS; Weiss MJ; Youngblood B; Long-Boyle JR; Gottschalk S; Meagher MM; Malech HL; Puck JM; Cowan MJ; Sorrentino BP
N Engl J Med; 2019 Apr; 380(16):1525-1534. PubMed ID: 30995372
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy model of X-linked severe combined immunodeficiency using a modified foamy virus vector.
Horino S; Uchiyama T; So T; Nagashima H; Sun SL; Sato M; Asao A; Haji Y; Sasahara Y; Candotti F; Tsuchiya S; Kure S; Sugamura K; Ishii N
PLoS One; 2013; 8(8):e71594. PubMed ID: 23990961
[TBL] [Abstract][Full Text] [Related]
4. A novel model of SCID-X1 reconstitution reveals predisposition to retrovirus-induced lymphoma but no evidence of gammaC gene oncogenicity.
Scobie L; Hector RD; Grant L; Bell M; Nielsen AA; Meikle S; Philbey A; Thrasher AJ; Cameron ER; Blyth K; Neil JC
Mol Ther; 2009 Jun; 17(6):1031-8. PubMed ID: 19337236
[TBL] [Abstract][Full Text] [Related]
5. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency.
van der Loo JC; Swaney WP; Grassman E; Terwilliger A; Higashimoto T; Schambach A; Hacein-Bey-Abina S; Nordling DL; Cavazzana-Calvo M; Thrasher AJ; Williams DA; Reeves L; Malik P
Gene Ther; 2012 Aug; 19(8):872-6. PubMed ID: 22551777
[TBL] [Abstract][Full Text] [Related]
6. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency.
Thornhill SI; Schambach A; Howe SJ; Ulaganathan M; Grassman E; Williams D; Schiedlmeier B; Sebire NJ; Gaspar HB; Kinnon C; Baum C; Thrasher AJ
Mol Ther; 2008 Mar; 16(3):590-8. PubMed ID: 18180772
[TBL] [Abstract][Full Text] [Related]
7. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Adams S; Howe SJ; Al Ghonaium A; Bayford J; Brown L; Davies EG; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra79. PubMed ID: 21865537
[TBL] [Abstract][Full Text] [Related]
8. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
9. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.
Schwarzwaelder K; Howe SJ; Schmidt M; Brugman MH; Deichmann A; Glimm H; Schmidt S; Prinz C; Wissler M; King DJ; Zhang F; Parsley KL; Gilmour KC; Sinclair J; Bayford J; Peraj R; Pike-Overzet K; Staal FJ; de Ridder D; Kinnon C; Abel U; Wagemaker G; Gaspar HB; Thrasher AJ; von Kalle C
J Clin Invest; 2007 Aug; 117(8):2241-9. PubMed ID: 17671654
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
11. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
Zhou S; Mody D; DeRavin SS; Hauer J; Lu T; Ma Z; Hacein-Bey Abina S; Gray JT; Greene MR; Cavazzana-Calvo M; Malech HL; Sorrentino BP
Blood; 2010 Aug; 116(6):900-8. PubMed ID: 20457870
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
Gaspar HB; Parsley KL; Howe S; King D; Gilmour KC; Sinclair J; Brouns G; Schmidt M; Von Kalle C; Barington T; Jakobsen MA; Christensen HO; Al Ghonaium A; White HN; Smith JL; Levinsky RJ; Ali RR; Kinnon C; Thrasher AJ
Lancet; 2004 Dec 18-31; 364(9452):2181-7. PubMed ID: 15610804
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of gene therapy for X-linked severe combined immunodeficiency.
Hacein-Bey-Abina S; Hauer J; Lim A; Picard C; Wang GP; Berry CC; Martinache C; Rieux-Laucat F; Latour S; Belohradsky BH; Leiva L; Sorensen R; Debré M; Casanova JL; Blanche S; Durandy A; Bushman FD; Fischer A; Cavazzana-Calvo M
N Engl J Med; 2010 Jul; 363(4):355-64. PubMed ID: 20660403
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.
Huston MW; Riegman AR; Yadak R; van Helsdingen Y; de Boer H; van Til NP; Wagemaker G
Hum Gene Ther; 2014 Oct; 25(10):905-14. PubMed ID: 25222508
[TBL] [Abstract][Full Text] [Related]
15. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency.
De Ravin SS; Wu X; Moir S; Anaya-O'Brien S; Kwatemaa N; Littel P; Theobald N; Choi U; Su L; Marquesen M; Hilligoss D; Lee J; Buckner CM; Zarember KA; O'Connor G; McVicar D; Kuhns D; Throm RE; Zhou S; Notarangelo LD; Hanson IC; Cowan MJ; Kang E; Hadigan C; Meagher M; Gray JT; Sorrentino BP; Malech HL; Kardava L
Sci Transl Med; 2016 Apr; 8(335):335ra57. PubMed ID: 27099176
[TBL] [Abstract][Full Text] [Related]
16. T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency.
Clarke EL; Connell AJ; Six E; Kadry NA; Abbas AA; Hwang Y; Everett JK; Hofstaedter CE; Marsh R; Armant M; Kelsen J; Notarangelo LD; Collman RG; Hacein-Bey-Abina S; Kohn DB; Cavazzana M; Fischer A; Williams DA; Pai SY; Bushman FD
Genome Med; 2018 Sep; 10(1):70. PubMed ID: 30261899
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
Cavazzana-Calvo M; Hacein-Bey S; de Saint Basile G; Gross F; Yvon E; Nusbaum P; Selz F; Hue C; Certain S; Casanova JL; Bousso P; Deist FL; Fischer A
Science; 2000 Apr; 288(5466):669-72. PubMed ID: 10784449
[TBL] [Abstract][Full Text] [Related]
18. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
19. Marking of peripheral T-lymphocytes by retroviral transduction and transplantation of CD34+ cells in a canine X-linked severe combined immunodeficiency model.
Suter SE; Gouthro TA; O'Malley T; Hartnett BJ; McSweeney PA; Moore PF; Felsburg PJ; Haskins ME; Henthorn PS
Vet Immunol Immunopathol; 2007 Jun; 117(3-4):183-96. PubMed ID: 17442404
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency.
Chinen J; Davis J; De Ravin SS; Hay BN; Hsu AP; Linton GF; Naumann N; Nomicos EY; Silvin C; Ulrick J; Whiting-Theobald NL; Malech HL; Puck JM
Blood; 2007 Jul; 110(1):67-73. PubMed ID: 17369490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
